Thymus-Derived TR006
Cross-source consensus on Thymus-Derived TR006 from 1 sources and 4 claims.
1 sources · 4 claims
Benefits
Risks & contraindications
Comparisons
Where it comes from
Highlighted claims
- ATT-Heart uses autologous thymus tissue rather than peripheral blood as the source for Tregs. — Protocol for a phase I single-centre dose escalation trial of autologous thymus derived regulatory T cells in paediatric heart transplant recipients to prevent cardiac allograft vasculopathy (ATT-Heart)
- Using discarded thymus tissue avoids the limited blood-draw volumes available in paediatric patients. — Protocol for a phase I single-centre dose escalation trial of autologous thymus derived regulatory T cells in paediatric heart transplant recipients to prevent cardiac allograft vasculopathy (ATT-Heart)
- Thymus tissue is presented as a rich source of higher-quality Tregs with stronger suppressive capacity than peripheral-blood Tregs. — Protocol for a phase I single-centre dose escalation trial of autologous thymus derived regulatory T cells in paediatric heart transplant recipients to prevent cardiac allograft vasculopathy (ATT-Heart)
- Age-related thymic atrophy may reduce starting material in older adolescents, so manufacturing feasibility across ages is a secondary objective. — Protocol for a phase I single-centre dose escalation trial of autologous thymus derived regulatory T cells in paediatric heart transplant recipients to prevent cardiac allograft vasculopathy (ATT-Heart)